Nicole Sweeny - 18 Jun 2025 Form 3 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Role
Chief Commercial Officer
Signature
/s/ Benjamin Palleiko, Attorney-in-Fact
Issuer symbol
KALV
Transactions as of
18 Jun 2025
Net transactions value
$0
Form type
3
Filing time
25 Aug 2025, 21:33:15 UTC
Previous filing
13 Feb 2023
Next filing
25 Aug 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Sweeny Nicole Chief Commercial Officer C/O KALVISTA PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 901E, CAMBRIDGE /s/ Benjamin Palleiko, Attorney-in-Fact 25 Aug 2025 0001827505

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding KALV Restricted Stock Unit 18 Jun 2025 Common Stock 100,000 $0.000000 Direct F1, F2
holding KALV Restricted Stock Unit 18 Jun 2025 Common Stock 80,000 $0.000000 Direct F2, F3
holding KALV Employee Stock Option 18 Jun 2025 Common Stock 100,000 $9.51 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/16th of the total number of shares subject to the Restricted Stock Unit ("RSU") shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on May 21, 2025, subject to continued service through each vesting date.
F2 Each RSU represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
F3 1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on August 22, 2024, subject to continued service through each vesting date.
F4 The option vests over a 4 year period: 25% on June 24, 2024, after which 1/48th of the total shares vest monthly, subject to continued service through each vesting date.